Showing 21-30 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Defining and applying neo-epitope specific TCRs for engineered cell therapy | Benaroya Research Institute at Virginia Mason | Aïsha Callebaut | Cures | 01-March-2023 to 28-February-2026 | $205,273.00 |
| Platforms for Cross-Therapeutic Profiling and Mechanistic Studies of Immune-Modifying Therapies in Type 1 Diabetes | Benaroya Research Institute at Virginia Mason | Dan Campbell | Cures | 01-March-2026 to 28-February-2029 | $1,045,621.50 |
| Assessing and mitigating T cell recognition of iPSC derived endocrine cells in Type 1 Diabetes | Benaroya Research Institute at Virginia Mason | Eddie James | Cures | 01-June-2024 to 31-May-2026 | $500,000.00 |
| Long-read approaches to identify coding, non-coding, and structural variation that contributes to T1D risk | Benaroya Research Institute at Virginia Mason | Eddie James | Cures | 01-September-2024 to 28-February-2026 | $150,000.00 |
| Cooperative harmonization and validation of an islet-specific AIM assay | Benaroya Research Institute at Virginia Mason | Karen Cerosaletti | Cures | 01-February-2024 to 31-January-2027 | $299,998.00 |
| New lipid biomarker to predict early risk for Type 1 diabetes | Beth Israel Deaconess Medical Center Inc | Barbara Kahn | Cures | 01-September-2024 to 31-August-2027 | $899,997.53 |
| Integration of Slow-Release A1AT-loaded Nanoparticles for Enhanced Cell Therapy in Type 1 Diabetes | Beth Israel Deaconess Medical Center Inc | Giuseppe Pettinato | Cures | 01-October-2024 to 31-July-2026 | $200,000.00 |
| Determining the role of new genes that may be involved in Type 1 Diabetes Pathogenesis | Beth Israel Deaconess Medical Center Inc | Ismail Syed | Cures | 01-June-2024 to 31-October-2025 | $199,999.67 |
| Reducing Health Disparities and Improving Outcomes in Type 1 Diabetes Through a Novel Community-Focused Digital Care Model | Blue Circle Health | Leonard D’Avolio | Mission | 01-January-2026 to 31-December-2028 | $1,500,000.00 |
| Harnessing Neonatal Regulatory T Cells for Precision Immunotherapy in Type 1 Diabetes | Boston Children’s Hospital | Ayano Kohlgruber | Cures | 01-March-2026 to 28-February-2031 | $998,713.47 |